Patents Assigned to Neonc Technologies Inc.
-
Patent number: 11559508Abstract: The present invention provides for a method of treating a disease such as cancer, comprising the step of administering to a patient a therapeutically effective amount of a perillyl alcohol derivative such as a perillyl alcohol ester, or an isoperillyl alcohol derivative such as an isoperillyl alcohol ester. The derivative may be a perillyl alcohol or an isoperillyl alcohol conjugated with a therapeutic agent such as valproic acid. The route of administration may vary, including inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.Type: GrantFiled: April 18, 2018Date of Patent: January 24, 2023Assignee: NEONC TECHNOLOGIES, INC.Inventors: Thomas Chen, Daniel Levin, Satish Puppali
-
Patent number: 11479554Abstract: A pharmaceutical composition is provided which includes perillyl alcohol conjugated with a therapeutic agent and further includes and a hydrolyzable acylated aliphatic tail. A method of using the pharmaceutical composition is also provided for treating a condition or disease of a patient, e.g., cancer.Type: GrantFiled: May 18, 2020Date of Patent: October 25, 2022Assignee: NeOnc Technologies, Inc.Inventors: Thomas Chen, Daniel Levin, Satish Puppali
-
Patent number: 11147809Abstract: The present methods treat neurofibromatosis by a administering to a subject perillyl alcohol or iso-perillyl alcohol. The present methods also treat neurofibromatosis by administering to a subject a carbamate of perillyl alcohol, or a carbamate of iso-perillyl alcohol. The perillyl alcohol carbamate may comprise perillyl alcohol conjugated with rolipram or temozolomide.Type: GrantFiled: June 30, 2017Date of Patent: October 19, 2021Assignee: NeOnc Technologies, Inc.Inventor: Thomas Chen
-
Patent number: 11077104Abstract: The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.Type: GrantFiled: September 6, 2018Date of Patent: August 3, 2021Assignee: NeOnc Technologies, Inc.Inventors: Thomas Chen, Daniel Levin, Satish Pupalli
-
Patent number: 10899691Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.Type: GrantFiled: September 19, 2019Date of Patent: January 26, 2021Assignee: NeOnc Technologies, Inc.Inventors: Thomas Chen, Daniel Levin, Satish Puppalli
-
Patent number: 10858305Abstract: NEO218 (3-bromo-2-oxo-propionic acid 4-isopropenyl-cyclohex-1-enylmethyl ester), (see formula 1), is a novel molecule that was generated by covalent fusion of two unrelated agents: 3-bromopyruvate (3-BF; an alkylating agent that Inhibits cancer cell metabolism) and perillyi alcohol (POH; a natural monoterpene with anticancer properties). Methods of synthesizing NBO218, pharmaceutical compositions comprising NBO218 and methods of treating cancer using NBO218 are also disclosed.Type: GrantFiled: November 29, 2017Date of Patent: December 8, 2020Assignee: NeOnc Technologies, Inc.Inventor: Thomas Chen
-
Patent number: 10696680Abstract: A pharmaceutical composition is provided which includes perillyl alcohol conjugated with a therapeutic agent and further includes and a hydrolyzable acylated aliphatic tail. A method of using the pharmaceutical composition is also provided for treating a condition or disease of a patient, e.g., cancer.Type: GrantFiled: September 10, 2018Date of Patent: June 30, 2020Assignee: NeOnc Technologies, Inc.Inventors: Thomas Chen, Daniel Levin, Satish Puppali
-
Patent number: 10457618Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.Type: GrantFiled: July 26, 2016Date of Patent: October 29, 2019Assignee: NeOnc Technologies, Inc.Inventors: Thomas Chen, Daniel Levin, Satish Puppali
-
Patent number: 10092562Abstract: The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.Type: GrantFiled: January 18, 2017Date of Patent: October 9, 2018Assignee: NeOnc Technologies, inc.Inventors: Thomas Chen, Daniel Levin, Satish Pupalli
-
Patent number: 9987237Abstract: The present invention provides for a method of treating a disease such as cancer, comprising the step of administering to a patient a therapeutically effective amount of an isomer or analog of monoterpene or sesquiterpene (or its derivative), such as an isoperillyl alcohol. The present invention also provides for a method of treating a disease comprising the step of administering to a patient a therapeutically effective amount of a derivative of an isomer or analog of monoterpene or sesquiterpene, such as an isoperillyl alcohol carbamate. The derivative may be an isoperillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The route of administration may vary, including inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.Type: GrantFiled: August 24, 2015Date of Patent: June 5, 2018Assignee: NeOnc Technologies, Inc.Inventors: Thomas Chen, Daniel Levin, Satish Pupalli, Daniel Anthony Dickman
-
Patent number: 9987271Abstract: A method of treating nasopharyngeal carcinoma in a mammal includes delivering to the mammal a therapeutically effective amount of a perillyl alcohol (POH) carbamate which is a perillyl alcohol conjugated with temozolomide (TMZ).Type: GrantFiled: February 10, 2017Date of Patent: June 5, 2018Assignee: NeOnc Technologies, Inc.Inventor: Thomas Chen
-
Patent number: 9913838Abstract: A method for treating brain metastases of a cancer in a mammal includes administering to the mammal a therapeutically effective amount of a perillyl alcohol carbamate, such as TMZ-POH. The brain metastases can be originated or spread from breast cancer. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent, such as a chemotherapeutic agent. The chemotherapeutic agents that may be used in the present invention include a DNA alkylating agent, a topoisomerase inhibitor, an endoplasmic reticulum stress inducing agent, a platinum compound, an antimetabolite, an enzyme inhibitor, and a receptor antagonist.Type: GrantFiled: October 8, 2014Date of Patent: March 13, 2018Assignee: NeOnc Technologies, Inc.Inventor: Thomas Chen
-
Patent number: 9765081Abstract: A pharmaceutical composition is provided which includes perillyl alcohol conjugated with a therapeutic agent and further includes and a hydrolyzable acylated aliphatic tail. A method of using the pharmaceutical composition is also provided for treating a condition or disease of a patient, e.g., cancer.Type: GrantFiled: March 17, 2017Date of Patent: September 19, 2017Assignee: NeOnc Technologies, Inc.Inventors: Thomas Chen, Daniel Levin, Satish Puppali
-
Patent number: 9700524Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.Type: GrantFiled: February 10, 2016Date of Patent: July 11, 2017Assignee: NeOnc Technologies Inc.Inventors: Thomas Chen, Daniel Levin, Satish Puppali
-
Patent number: 9663428Abstract: The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene for sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.Type: GrantFiled: August 8, 2014Date of Patent: May 30, 2017Assignee: NeOnc Technologies Inc.Inventors: Thomas Chen, Daniel Levin, Satish Pupalli
-
Patent number: 9657026Abstract: A pharmaceutical composition is provided which includes perillyl alcohol conjugated with a therapeutic agent and further includes and a hydrolyzable acylated aliphatic tail. A method of using the pharmaceutical composition is also provided for treating a condition or disease of a patient, e.g., cancer.Type: GrantFiled: June 24, 2016Date of Patent: May 23, 2017Assignee: NeOnc Technologies Inc.Inventors: Thomas Chen, Daniel Levin, Satish Pupalli
-
Patent number: 9580372Abstract: The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.Type: GrantFiled: August 8, 2014Date of Patent: February 28, 2017Assignee: NeOnc Technologies Inc.Inventors: Thomas Chen, Daniel Levin, Satish Pupalli
-
Patent number: 9522918Abstract: A pharmaceutical composition is provided which includes perillyl alcohol conjugated with a therapeutic agent and further includes and a hydrolyzable acylated aliphatic tail. A method of using the pharmaceutical composition is also provided for treating a condition or disease of a patient, e.g., cancer.Type: GrantFiled: February 11, 2016Date of Patent: December 20, 2016Assignee: NeOnc Technologies, Inc.Inventors: Thomas Chen, Daniel Levin, Satish Pupalli
-
Patent number: 9499461Abstract: The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.Type: GrantFiled: August 26, 2011Date of Patent: November 22, 2016Assignee: NeOnc Technologies, Inc.Inventors: Thomas Chen, Daniel Levin, Satish Puppali
-
Patent number: 9480659Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.Type: GrantFiled: August 4, 2015Date of Patent: November 1, 2016Assignee: NeOnc Technologies, Inc.Inventors: Thomas Chen, Daniel Levin, Satish Puppali